Ajanta Pharma announced Q3FY23 results Q3FY23: Revenue from operations at Rs 972 crore against Rs 838 crore; up 16%. EBITDA at Rs 170 crore against Rs 240 crore; EBITDA at 17% of revenue from operations. Adjusted EBITDA stands at Rs 207 crore against Rs 240 crore; Adjusted EBITDA at 21% of revenue from operations. This is after adjusting forex derivative loss of Rs 37 crore included in other expenses with forex gain in other income. Profit after tax at Rs 135 crore against Rs 192 crore; PAT at 14% of revenue from operations. 9MFY23: Revenue from operations at Rs 2,861 crore against Rs 2,471 crore, up 16%. EBITDA at Rs 588 crore against Rs 723 crore; EBITDA at 21% of revenue from operations. Adjusted EBITDA stands at Rs 631 crore against Rs 723 crore; Adjusted EBITDA at 22% of revenue from operations. This is after adjusting forex derivative loss of Rs 43 crore included in other expenses with forex gain in other income. Profit after tax at Rs 466 crore against Rs 561 crore, PAT at 16% of revenue from operations. Result PDF